“Chemgenix, Heartware, Metabolic and
Pharmaxis among the top picks for 06/07”
(Radar Investor Relations survey of
16 leading biotech analysts)
“Metabolic Pharmaceutical’s impressive
turnaround”
(Bioshares, 13 Oct 2006)
“MBP is a very different company than it was
two years ago…the product line has been
significantly expanded”
(ABN-AMRO Morgans’ weekly
healthcare newsletter, 17 Oct 2006)
“Metabolic was a "screaming bargain at 45c"
… a "super-binary" company that seems set
to go well if the Phase 2 trial results are
positive.”
(Patersons analyst Dr Matthijs
Smith quoted in Biotechnology
News, 20 October 2006)
“Chemgenix, Heartware, Metabolic andPharmaxis among the top...
Add to My Watchlist
What is My Watchlist?